Clinical trialObsCompleted
Identification of Biomarkers for Early Detection of Pancreatic Cancer
Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- February 2005
- Expected end
- April 2011
- Enrollment
- 75 participants
- Sites
- 1
- Primary outcomes
- Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer; Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis
- Sponsor
- Other
- Results posted
- No
- Last update
- 9 March 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
OBJECTIVES: * Identify specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer. * Analyze serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis. OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS). PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Intervention public domain (ClinicalTrials.gov)
Genetic: protein expression analysis. Venous blood collection
Intervention public domain (ClinicalTrials.gov)
Other: laboratory biomarker analysis. Venous blood collection
Intervention public domain (ClinicalTrials.gov)
Other: mass spectrometry. Venous blood collection
Intervention public domain (ClinicalTrials.gov)
Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry. Venous blood collection
Primary outcome public domain (ClinicalTrials.gov)
Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer. Time frame: Upon collection when patient agrees to provide a one time venous blood collection.
Primary outcome public domain (ClinicalTrials.gov)
Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis. Time frame: After separation from the plasma.
Eligibility public domain (ClinicalTrials.gov)
DISEASE CHARACTERISTICS: * Diagnosis of pancreatic cancer * Newly diagnosed disease * Planning to undergo surgery or other treatment for pancreatic cancer at Karmanos Cancer Institute or its affiliates PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 75 participants (actual).